As the OS results of the two studies were published in 2021, we conducted a meta-analysis to provide more reliable and stable evidence to determine the PFS and OS benefit in the combination therapy for advanced EGFR-mutant NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.